{"preliminary_commentary":{"by_channel":{"x_thread":21,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06935409\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"ARTEMIS-011","nct_id":"NCT06935409","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=artemis-011-nct06935409. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Study participants in the experimental group shall continue to receive HS-20093 by intravenous infusion at a dose of 12.0 mg/kg, once every 3 weeks (Q3W) with a 21-day treatment cycle. Treatment shall continue until objective disease progression (excluding cases of treatment beyond PD or crossover treatment) or until other criteria for termination of study treatment specified in the protocol are met.","label":"HS-20093","type":"EXPERIMENTAL"},{"description":"Study participants in the control arm will receive gemcitabine in combination with docetaxel. Gemcitabine (1000 mg/m2) will be administered intravenously over approximately 30 minutes on Days 1 and 8 of each 21-day treatment cycle, followed by docetaxel (75 mg/m2) on Day 8, intravenously over approximately 1 hour until objective disease progression or other criteria for treatment discontinuation are met.","label":"Gemcitabine combined with docetaxel","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-09-07","type":"ACTUAL"},"conditions":["Osteosarcoma"],"enrollment":{"count":122,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"HS-20093","otherNames":[],"type":"DRUG"},{"name":"Gemcitabine combined with docetaxel","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-19","lead_sponsor":"Hansoh BioMedical R&D Company","official_title":"A Randomized, Controlled, Open-label, Multicenter Phase III Clinical Study to Evaluate the Efficacy and Safety of HS-20093 for Injection Versus Gemcitabine in Combination With Docetaxel in the Treatment of Osteosarcoma After Previous Second-line Treatment Failure (ARTEMIS-011)","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2026-06-17","type":"ACTUAL"},"primary_outcomes":[{"measure":"PFS assessed by IRC as per RECIST 1.1 criteria","timeFrame":"From the date of randomization to documented progressive disease, death, lost to follow-up, or withdrawal by the participant; Up to approximately 5 years."}],"references":[],"start_date":{"date":"2025-04-25","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure","url":"https://clinicaltrials.gov/study/NCT06935409"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/artemis-011-nct06935409"}